Connect Biopharma is trading 7.07% up at $1.97, with investor positioning ahead of expected September 2026 topline results from the Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart.
- Enrollment is complete, and the company described the data as a key development milestone.
- Broader U.S. markets were lower, making the gain company-specific rather than market-driven.